Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Redline Alert Anthrax Test Cleared For Use In Clinical Laboratories

This article was originally published in The Gray Sheet

Executive Summary

Tetracore's Redline Alert is the first antibody test for anthrax to gain 510(k) clearance from FDA

You may also be interested in...



West Nile Virus Assay Makers Race To Meet FDA’s Testing Needs By Summer

Focus Technologies expects to be the first company to offer a West Nile Virus clinical diagnostic in the U.S

Microbiology Panel Outlines Predicate Device Precedent For Anthrax Testing

Preamendments diagnostic tests for anthrax should be categorized as Class II devices with special controls, according to CDRH's Microbiology Devices Panel

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel